Page 22 - Median Technologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31st, 2023

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31st, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalEmmanuelle leyguesCaroline carmagnolGhislaine gasparettoHead of corporate marketing financial communicationsMedian technologiesArtificial intelligenceEuronext growthCorporate marketingFinancial communications

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of February 28th, 2023

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations. Regulatory News: Median Technologies (Paris:ALMDT): Total number of shares

France generalDennis riedlEmmanuelle leyguesGhislaine gasparettoCaroline carmagnolHead of corporate marketing financial communicationsMedian technologiesArtificial intelligenceEuronext growthCorporate marketing financial communications

Median Technologies Announces Completion of the Q-Submission Phase with the FDA for its iBiopsy Lung Cancer Screening CADe/CADx Software as Medical Device

Further to the Q-submission phase completion, Median’s iBiopsy LCS CADe/CADx SaMD pivotal study protocols are now finalized and ready for study execution.

United statesFrance generalCade cadxLcs cade cadxSoftware as medical device saDrug administrationMedian technologiesUnited states foodBiopsy lung cancer screeningMedical deviceFredrik brag

Median Technologies to present new and breakthrough results for its iBiopsy Lung Cancer Screening CADe/CADx Software as Medical Device at the European Congress of Radiology, taking place March 1-5 2023 in Vienna, Austria

New results, obtained on a very large cohort of 9,863 patients show drastically improved performance of the iBiopsy® LCS CADe/CADx Software as Medical Device (SaMD) with a sensitivity of 96.5% at

France generalCade cadxDennis riedlEmmanuelle leyguesLcs cade cadxGhislaine gasparettoCaroline carmagnolEuropean society of radiologyEuropean congressHead of corporate marketing financial communicationsSoftware as medical device saSoftware as medical devices saMedical deviceLung cancer screeningFredrik bragEuropean society

Median Technologies Announces Completion of the Q-Submission Phase with the FDA for its iBiopsy Lung Cancer Screening CADe/CADx Software as Medical Device

The Q-submission phase was initiated on May 2, 2022 with the FDA. The Q-submission phase aims at clarifying and implementing the FDA's expectations on key topics including pivotal study protocols.

United statesFrance generalCade cadxDennis riedlEmmanuelle leyguesLcs cade cadxGhislaine gasparettoCaroline carmagnolHead of corporate marketing financial communicationsSoftware as medical device saDrug administrationSoftware of medical devices saUnited states foodLung cancer screeningMedical deviceMedian technologies